Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
SAN FRANCISCO, April 20, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the addition of 80 new panels alongside ...
Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic ...
A genetic testing company you've never heard of could become a household name as it takes on 23andMe
If the future of healthcare is in your DNA, there's a war brewing over how to harness the information it contains without causing harm to patients. Today, there are two main ways to take a peak at ...
Invitae has launched a cancer blood test designed to detect the minimal residual disease left over from solid tumors to help gauge a patient’s risk of recurrence and track their response to treatments ...
Shares of genetic-testing company Invitae (NVTA +0.00%) rose over 13% today on an upbeat day for the stock market. The S&P 500 rose over 1.5% as investors cheered plans by some countries and U.S.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results